Barclays Maintains Equal-Weight Rating for Bausch & Lomb: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Barclays has maintained its Equal-Weight rating on Bausch & Lomb (NYSE:BLCO) and increased its price target from $17.00 to $18.00. Bausch & Lomb, a leading vision care company, was spun off from Bausch Health in 2022. It operates in vision care, surgical, and ophthalmic pharmaceuticals, holding the largest portfolio of eye care prescriptions. The stock is currently trading at $17.55, down 0.28% over the last 24 hours. An increase to $18.00 represents a 2.56% potential upside.
February 26, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains Equal-Weight on BLCO, raises target from $17 to $18. BLCO trades at $17.55, down 0.28%. The firm is a leader in vision care with a vast product portfolio.
The maintenance of an Equal-Weight rating by Barclays with an increased price target suggests a positive outlook on BLCO's stock, indicating a potential short-term upside. Given BLCO's position as a leader in the vision care market and its extensive product portfolio, this analyst action could positively influence investor sentiment and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100